
Extensive, late-stage radiopharmaceutical pipeline
Our core product pipeline, focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, has generated extensive clinical data that demonstrate the potential for efficacy and acceptable safety profile. We believe the targets and indications we are pursuing are well validated and are well suited for the delivery of therapeutic and diagnostic targeted radiation. The use of imaging to select patients for therapy is also a differentiated aspect of our commercial strategy.
Late-stage therapeutic pipeline
agent
PSMA1
CAIX2
LAT4
CD667
Early-stage therapeutic pipeline
agent
PSMA
CAIX
FAP
LAT
Precision medicine portfolio
agent
PSMA
PSMA
CAIX
LAT
1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
3. Trade name subject to final regulatory approval.
4. Large amino acid transporters 1 and 2.
5. Soft tissue sarcoma.
6. Platelet derived growth factor receptor alpha.
7. Cluster of differentiation 66.